Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SRRK 10.07.2024

Full Press ReleaseSEC FilingsOur SRRK Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.14.2025 - 43rd Annual JP Morgan Healthcare Conference
  • 01.08.2025 - Scholar Rock Highlights 2025 Strategic Priorities

Recent Filings

  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.14.2025 - 8-K Current report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 7, 2024--Scholar Rock Holding Corporation(Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that it has commenced an underwritten public offering for$275 millionof shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being offered byScholar Rock. In addition,Scholar Rockintends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the securities offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Scholar Rockintends to use the net proceeds from the offering to support commercialization of apitegromab, to advance its ongoing and future clinical programs, to further develop its technology platform to continue to advance its clinical and preclinical pipeline, and for working capital and other general corporate purposes.

J.P. Morgan Securities LLC,Jefferies LLCandPiper Sandler & Co.are acting as joint book-running managers for the offering.BMO Capital Markets Corp.,Wedbush Securities Inc.andRaymond James & Associates, Inc.are acting as co-managers for the offering.

An automatically effective shelf registration statement on Form S-3 relating to the offering of the securities described above was filed with theSecurities and Exchange Commission(SEC) onOctober 7, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with theSECand will be available on the SEC’s website located atwww.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting:J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions,1155 Long Island Avenue,Edgewood, NY11717, or by email atprospectus-eq_fi@jpmchase.comandpostsalemanualrequests@broadridge.com;Jefferies LLC, Attention:Equity Syndicate Prospectus Department,520 Madison Avenue,New York, NY10022, by telephone at 877-821-7388, or by email atprospectus_department@jefferies.com; orPiper Sandler & Co.,800 Nicollet Mall, J12S03,Minneapolis, MN55402, Attention: Prospectus Department, by telephone at 800-747-3924, or by email atprospectus@psc.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

AboutScholar Rock

Scholar Rockis a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade,Scholar Rockhas created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.

This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies,Scholar Rockworks every day to create new possibilities for patients.

Scholar Rock® is a registered trademark ofScholar Rock, Inc.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s intention to conduct an offering and sale of securities, the size of the offering, the completion of the proposed offering and the expected use of proceeds from the proposed offering. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Scholar Rock’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering and those risks more fully discussed in the section entitled“Risk Factors”in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter endedJune 30, 2024, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with theSEC. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, andScholar Rockundertakes no duty to update this information unless required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241007564559/en/

Scholar Rock:InvestorsRushmie NofsingerScholar Rockrnofsinger@scholarrock.comir@scholarrock.com857-259-5573MediaMolly MacLeodScholar Rockmmacleod@scholarrock.commedia@scholarrock.com802-579-5995

Source:Scholar Rock

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com